Salah Nabhan
Agios Pharmaceuticals
8 Papers
Salah Nabhan is an academic researcher from Agios Pharmaceuticals. The author has contributed to research in topics: Medicine & Enasidenib. The author has an hindex of 4, co-authored 5 publications.
Chat about Author
Papers
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study
Eytan M. Stein,Courtney D. DiNardo,Amir T. Fathi,Alice S. Mims,Keith W. Pratz,Michael R. Savona,Anthony S. Stein,Richard Stone,Eric S. Winer,Christopher S. Seet,Hartmut Döhner,Daniel A. Pollyea,James K. McCloskey,Olatoyosi Odenike,Bob Löwenberg,Gert J. Ossenkoppele,Prapti A. Patel,Mikhail Roshal,Mark G. Frattini,Frederik Lersch,Aleksandra Franovic,Salah Nabhan,Bin Fan,Sung Choe,Hongfang Wang,Bin Wu,Lei Hua,Caroline Almon,Michael Cooper,Hagop M. Kantarjian,Martin S. Tallman +30 more
TL;DR: Increases in total bilirubin were more frequently observed in patients treated with enasidenib, consistent with this inhibitor's known potential to inhibit UGT1A1, but did not appear to have significant clinical consequences.
186
Ivosidenib or Enasidenib Combined with Standard Induction Chemotherapy Is Well Tolerated and Active in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation: Initial Results from a Phase 1 Trial
Eytan M. Stein,Courtney D. DiNardo,Alice S. Mims,Michael R. Savona,Keith W. Pratz,Anthony S. Stein,Amir T. Fathi,Richard Stone,Daniel A. Pollyea,Daniel A. Pollyea,Olatoyosi Odenike,Bob Löwenberg,Hartmut Döhner,Gary J. Schiller,Ira Gupta,Salah Nabhan,Vickie Zhang,Caroline Almon,Michael Cooper,Martin S. Tallman +19 more
TL;DR: Ivosidenib or enasidenib combined with induction chemotherapy was generally well tolerated and one dose-limiting toxicity was observed.
32
Abstract PR03: A phase 1 trial of AG-270 in patients with advanced solid tumors or lymphoma with homozygous MTAP deletion
Rebecca S. Heist,Mrinal M. Gounder,Sophie Postel-Vinay,Frederick Wilson,Elena Garralda,Khanh T. Do,Geoffrey I. Shapiro,Patricia Martin-Romano,Gerburg M. Wulf,Michael Cooper,Caroline Almon,Salah Nabhan,Varsha Iyer,Yanwei Zhang,Kevin Marks,Elia Aguado-Fraile,Frank G. Basile,Keith T. Flaherty,Howard A. Burris +18 more
TL;DR: The primary objective of this study is to determine the maximum tolerated dose (MTD) of AG-270, a first-in-class, oral, potent, reversible inhibitor of methionine adenosyltransferase 2A (MAT2A), the key enzyme responsible for SAM synthesis.
4
A Phase 1 Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients With Advanced Myeloid Malignancies.
C. Dinardo,Amir T. Fathi,A. Kishtagari,Kapil N. Bhalla,Alfonso Quintás-Cardama,Sarah A Reilly,Caroline Almon,Caitlin Patriquin,Salah Nabhan,Kathleen Healy,Denice Hickman,Mike Collins,Alexis Khalil,Dillon Corrigan,Jessica Piel,Kelly Lyons,Kim Horrigan,Virna Schuck,Paul Martin,GiNell Elliott,David L Lahr,Mia Bosinger,Katie D'Aco,Gromoslaw A. Smolen,Murphy Hentemann,Sanam Loghavi,S. Agresta,Michael R. Savona,Eytan M. Stein +28 more
Pharmacokinetic/Pharmacodynamic Evaluation of Ivosidenib or Enasidenib Combined With Intensive Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed IDH1/2‐Mutant Acute Myeloid Leukemia
Bin Fan,Yue-qing Chen,Feng Yin,Lei Hua,Caroline Almon,Salah Nabhan,Michael Cooper,Hua Yang,Mohammad S. Hossain +8 more
TL;DR: In this population, the pharmacokinetics (PK), pharmacodynamics (PD), and PK/PD relationships for ivosidenib and enasidenib were characterized.